New Insights into Why Immunotherapy Fails and How to Overcome Resistance in Cancer Treatment
New research sheds light on why immunotherapy fails in many cancer patients and introduces promising strategies to overcome treatment resistance by targeting the protein sClever-1, paving the way for more effective cancer therapies.
Recent research published by the University of Birmingham and the University of Turku has uncovered crucial mechanisms behind the failure of immunotherapy in many cancer patients. Using advanced techniques, scientists identified a secreted form of the protein Clever-1, known as sClever-1, which plays a key role in immune suppression during cancer progression. Elevated levels of sClever-1 in the bloodstream are associated with resistance to anti-PD-1 therapies, a common class of cancer immunotherapies.
The study revealed that the investigational drug bexmarilimab, an anti-Clever-1 antibody, effectively inhibits the release of sClever-1, thereby potentially restoring immune system activity against tumors. This discovery provides a promising avenue for predicting which patients may not benefit from standard immunotherapy and highlights the potential of combination treatments that target sClever-1 to improve outcomes.
Lead researcher Professor Shishir Shetty from the University of Birmingham explained that high blood levels of sClever-1 could serve as a biomarker for immunotherapy resistance, allowing clinicians to tailor treatments more effectively. Similarly, Dr. Maija Hollmén from the University of Turku emphasized that reducing sClever-1 release may reprogram immune cells to fight cancer more efficiently.
The research, presented at the 19th International Congress of Immunology, analyzed plasma samples from 138 breast cancer patients, 193 individuals with advanced solid tumors, and 21 healthy donors. The findings indicate that inflammatory signals in the tumor microenvironment prompt macrophages to release sClever-1, which then impairs T cell responses by binding directly to these immune cells. This process effectively paralyzes the immune system’s ability to attack cancer cells.
Overall, these insights pave the way for new therapeutic approaches that can overcome immune evasion in cancer, potentially making immunotherapy accessible to more patients and improving long-term survival rates.
Source: https://medicalxpress.com/news/2025-09-immunotherapy-failure-patients-cancer.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Therapy Targets Astrocytes to Enhance Immune Response Against Glioblastoma
A novel therapeutic approach aims to enhance immune responses against glioblastoma by targeting astrocytes that suppress T cell activity, potentially opening new avenues for treatment.
Innovative Wearable Robot Adapts to Individual Movement Patterns for Stroke and ALS Patients
A new wearable robotic device personalizes support for stroke and ALS patients by adapting to individual arm movement patterns through advanced machine learning, improving daily function and independence.
Research Links Certain Antibodies in Lupus Patients to Increased Risk of Blood Clots
A breakthrough study identifies specific antibodies in lupus patients that significantly increase their risk of blood clots, paving the way for better risk assessment and targeted treatments.
Harnessing Immune Cell Growth Factors to Enhance Lung Repair After Viral Inflammation
New research uncovers how macrophage-produced growth factors, especially oncostatin M (OSM), promote lung tissue repair after viral damage, offering promising therapeutic insights.